tiprankstipranks

Amgen’s tarlatamab approved by MHRA for small cell lung cancer

Amgen’s tarlatamab approved by MHRA for small cell lung cancer

The Medicines and Healthcare products Regulatory Agency of the United Kingdom announced it has approved the medicine tarlatamab, Imdyllytra, to treat adult patients with small cell lung cancer that has spread throughout the lungs and/or to other parts of the body. “This approval has been granted under Project Orbis, an innovative programme that allows participating regulators to review and approve applications for promising cancer treatments quickly and efficiently. SCLC is one of the two main forms of primary lung cancer, accounting for around 1 in 7 of all lung cancers. It is less common than non-small-cell lung cancer and spreads more quickly,” the MHRA stated. The new marketing authorization was granted on December 31 to Amgen (AMGN) Limited.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue